What is NanoMedical Systems?
NanoMedical Systems operates at the intersection of nanotechnology and pharmacology, specializing in the development of sophisticated drug-delivery devices. At the core of its value proposition is the nStrada nanofluidics platform, which utilizes high-density arrays of precision nanochannels to facilitate the sustained release of biologics and therapeutic agents. Unlike conventional polymer-based delivery mechanisms that often suffer from unpredictable burst effects, the NanoMedical Systems architecture ensures a consistent, reliable release profile. The company maintains a diverse portfolio of delivery solutions, ranging from passive implants to actively controlled, refillable systems, positioning itself as a critical partner for pharmaceutical enterprises and healthcare providers seeking to optimize patient outcomes through precision medicine.
How much funding has NanoMedical Systems raised?
NanoMedical Systems has raised a total of $6.5M across 2 funding rounds:
Unspecified
$2.3M
Private Equity
$4.1M
Unspecified (2012): $2.3M, investors not publicly disclosed
Private Equity (2017): $4.1M, investors not publicly disclosed
Key Investors in NanoMedical Systems
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for NanoMedical Systems?
With the recent influx of capital, NanoMedical Systems is well-positioned to accelerate the commercialization of its next-generation delivery systems. The strategic focus will likely shift toward scaling manufacturing capabilities to meet the rigorous demands of global pharmaceutical partners and expanding clinical validation for its refillable and actively controlled platforms. As the company matures, the emphasis will remain on enhancing the reliability and scalability of its nanofluidics technology, ensuring that it remains the gold standard for long-term, subcutaneous drug administration. Future growth will be driven by the integration of these devices into broader therapeutic pipelines, potentially disrupting traditional delivery paradigms in chronic disease management.
See full NanoMedical Systems company page
